surmount-1 trial tirzepatide obesity without diabetes weight loss SURMOUNT-1: Drastically Reduces in Obese Patients With respect to the SURMOUNT-MAINTAIN
Description
Tell your healthcare team if you are planning surgery or other procedure that uses anesthesia or deep sedation
Months three through six A turning point often emerges during this period
Like the GLP-1, it also reduces gastric emptying but has the added effect of suppressing appetite in the hypothalamus
As of May 2026, tirzepatide is only available as a subcutaneous injection
This approach manages blood glucose without compromising foetal nutrition
